Are you a Veteran of the United States Armed Forces?

Please complete a short survey about prostate cancer care for Veterans to help us learn what's working well and what needs improvement in the care Veterans receive.

Veterans prostate cancer care survey Complete the Survey

Genomic test does not increase active surveillance acceptance for treating favorable-risk prostate cancer

Genomic Testing Image

The results from a trial evaluating the Genomic Prostate Score did not find an increase in active surveillance acceptance amongst a population of predominantly Black men with favorable-risk prostate cancer.

The Genomic Prostate Score (GPS) did not increase active surveillance acceptance compared with conventional risk counseling among patients with favorable-risk prostate cancer, according to data published in the Journal of Clinical Oncology.

Read the full article here.

 


Source: Matthew Fowler - Cancer Network

 

Share